Vibrating mesh Nebulizer-Aerogen

During the SARS outbreak, anecdotal reports highlighted that infected persons receiving ae rosol therapies may have facilitated the transmission of SARS under certain circumstances. Nebulizer treatment with jet nebulizers was proposed as being contributory among other aerosol-generating techniques, although the causal evidence has not been substantiated.

Vibrating mesh nebulizers (VMNs) have been demonstrated to have significantly reduced fugitive emissions compared to the jet nebulizers due to the combination of lower or no-airflow requirement, and with the use of the valve system. In addition, the VMN product design does not allow contact of contaminated fluids with the aerosol-producing mechanism and/or medication reservoir.

Aerogen’s vibrating mesh nebulizer (VMN) is a high-performance, highly efficient aerosol drug-delivery device, increasing drug delivery to the lungs up to six-fold compared to the jet nebulizer. VMN may pose a lower risk of infection by averting the challenges of jet nebulizers that require breaking the circuit during mechanical ventilation to treat the patient. Aerogen VMN also reduces re-nebulization of condensate as it sits above the circuit.

Aerogen’s VMN inline circuit design, removing the need to break the ventilation circuit when nebulizing, provides a significant safety advantage in patients suffering from droplet-spread infections. When the circuit is broken to insert a gas-driven nebulizer, particularly at the patient end of the circuit, the resulting droplet spray may contaminate the room and create a risk to caregivers. This risk can be eliminated using an Aerogen VMN closed system.

Aerogen VMN can also be used inline during other types of respiratory support in the acute care settings, including HFOV, NIV, CPAP, and HFNC2.
It is suitable for a wide range of physician-prescribed medications and has very low residual volume, fast treatment time, and ability to nebulize a variety of solutions and suspensions.
In addition, Aerogen’s efficient drug delivery to the lungs has demonstrated clinically meaningful outcomes. Aerogen’s technology is, therefore, ideally placed to help deliver safe and industry-leading care to patients who may be suffering from coronavirus.